方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 贝叶斯Ⅰ期临床试验× | 剂量-反应分析× | |
|---|---|---|
| 领域 | 流行病学 | 流行病学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1990 | Conceptual roots 16th century; modern epidemiological application mid-20th century |
| 提出者≠ | O'Quigley, Pepe & Fisher (Continual Reassessment Method) | Paracelsus (conceptual foundation); formalized by John Snow and later Bradford Hill |
| 类型≠ | Adaptive Bayesian dose-finding design | Quantitative analytical method |
| 开创性文献≠ | O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. DOI ↗ | Rothman, K. J., Greenland, S., & Lash, T. L. (2008). Modern Epidemiology (3rd ed.). Lippincott Williams & Wilkins. ISBN: 978-0781755641 |
| 别名 | Bayesian dose-finding trial, CRM trial, continual reassessment method trial, Bayesian dose-escalation study | exposure-response analysis, concentration-response modeling, dose-response modeling, DRA |
| 相关≠ | 5 | 4 |
| 摘要≠ | A Bayesian Phase I clinical trial uses prior probability models and sequential Bayes updating to find the maximum tolerated dose (MTD) of a new agent. Unlike the traditional 3+3 rule-based escalation, the Bayesian approach revises a dose-toxicity curve continuously as each patient's outcome is observed, allowing faster convergence to the true MTD while minimising exposure of patients to unsafe or subtherapeutic doses. | Dose-response analysis quantifies the relationship between the magnitude of an exposure (the dose) and the probability or rate of an outcome (the response). It is a core analytical strategy in epidemiology and toxicology, providing evidence that increasing exposure systematically increases — or decreases — the risk of disease. A demonstrated dose-response gradient is one of Bradford Hill's classic criteria supporting causal inference. |
| ScholarGate数据集 ↗ |
|
|